Lung Injury: Clinical Trials

92 trials for Lung Injury, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

42 completed, 23 terminated, 14 unknown, 6 recruiting. 92 Phase 3, 22 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 392Completed 42, Terminated 23, Unknown 14, Recruiting 6, Not yet recruiting 3, Withdrawn 3, Active not recruiting 1
Phase 222Completed 9, Terminated 5, Recruiting 3, Unknown 3, Not yet recruiting 1, Withdrawn 1

Follow Lung Injury: new trials by email Literature Review of Lung Injury trials Research Report on Lung Injury

Trials (filtered) newest first · largest first

All 92 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Ondansetron for the Prevention of Patient Self-Inflicted Lung Injury in Patients With ARDS - Pilot RCT
Ondansetron hydrochloride 8 mg IV Q8H, 0.9 % Normal Saline 10 ml - ARDS (Acute Respiratory Distress Syndrome), Invasive Mechanical Ventilation
Phase 2 / Phase 3Not yet recruitingCentre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal762026-10-012026-05-14
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
[18F]FAPI-74, 18F-FAPI-74 PET/CT Imaging - Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation
Phase 3RecruitingNational Heart, Lung, and Blood Institute (NHLBI)2102026-09-182026-10-26
RECOMMEND Platform Trial
Liberal RBC Transfusion, Restrictive RBC Transfusion - Extracorporeal Membrane Oxygenation Complication, ARDS (Acute Respiratory Distress Syndrome)
Phase 3RecruitingAustralian and New Zealand Intensive Care Research Centre6002026-03-232026-05-13
Dexamethasone Regimens for BPD Prevention in Preterm Infants
Dexamethasone. Dart, Dexametasone. Medium - Infant, Premature, Bronchopulmonary Dysplasia (BPD)
Phase 3Not yet recruitingThe Children's Hospital of Zhejiang University School of Medicine9702026-02-012025-11-24
A Study on the Treatment of Patients With Acute Lung Injury Caused by Sepsis Through Microbiota Transplantation
Placebo control group, Human-derived active intestinal bacterial liquid group - Acute Respiratory Distress Syndrome (ARDS), Acute Lung Injury(ALI)
Phase 2 / Phase 3RecruitingShanghai University of Traditional Chinese Medicine602025-12-102026-01-15
Efficacy of Nebulised Inhalational Steroids in Neonates With Meconium Aspiration Syndrome
Budesonide, Normal Saline - Meconium Aspiration Syndrome
Phase 3CompletedKhyber Teaching Hospital602025-11-282026-08-13
Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)
Air-sham, Zelpultide alfa - Bronchopulmonary Dysplasia
Phase 2 / Phase 3RecruitingAirway Therapeutics, Inc.3662025-02-032026-11-17
Enhancing Lung Health in Kids With Structural Lung Damage and Malformations: Azithromycin (AZI) for Airway Infection Prevention
Azithromycin 40 MG/ML, Placebo - Tracheomalacia, Bronchopulmonary Dysplasia (BPD)
Phase 3Not yet recruitingCopenhagen University Hospital, Rigshospitalet1502024-09-012024-05-14
Caffeine as an Adjuvant Therapy for Late Preterm Infants With Respiratory Distress
Caffeine citrate, Placebo - Prematurity, Respiratory Disease
Phase 2 / Phase 3RecruitingMinistry of Health, Saudi Arabia1342023-10-122025-06-27
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
radiotherapy, Platinum-Based Drug, Immunotherapy - Non-small Cell Lung Cancer Stage III
Phase 3UnknownZhejiang Cancer Hospital1052023-09-152023-09-13
Nebulized Heparin for Prevention of Acute Lung Injury in Smoke Inhalation Injury
Heparin, Normal Saline - Smoke Inhalation Injury, Acute Lung Injury
Phase 3CompletedAin Shams University882023-06-012024-12-12
Individualized Positive End-expiratory Pressure Guided by End-expiratory Lung Volume in the Acute Respiratory Distress Syndrome
Invasive Mechanical ventilation, Neuromuscular Blocking Agents, Prone positioning - Respiratory Distress Syndrome, Adult
Phase 3TerminatedFondazione Policlinico Universitario Agostino Gemelli IRCCS182022-11-012025-09-30
Effect of Caffeine Versus Probiotic on Preterm Neonates With Bronchopulmonary Dysplasia
Caffeine, Probiotic Formula - Bronchopulmonary Dysplasia
Phase 3UnknownTanta University902022-06-302023-01-12
Efficacy and Safety of Pirfenidone Capsules in the Treatment of Pneumoconiosis
Pirfenidone Capsules, placebo capsules - Pneumoconiosis
Phase 3RecruitingBeijing Continent Pharmaceutical Co, Ltd.2722022-06-072025-11-24
Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19
ZYESAMI™ (aviptadil acetate), Placebo, Nebulized administration of ZYESAMI™ or Placebo - SARS-CoV 2, COVID
Phase 3WithdrawnAPR Applied Pharma Research s.a.2021-12-152026-05-14
Intratracheal Budesonide With Surfactant to Prevent Bronchopulmmonary Dysplasia.
Poractant Alfa Intratracheal Suspension [Curosurf], Budesonide 0.5 MG/ML - Bronchopulmonary Dysplasia, Respiratory Distress Syndrome in Premature Infant
Phase 3UnknownHospital Clinic of Barcelona502021-10-012021-09-13
Effect of Autologous Cord Blood Mononuclear Cells for Treatment of Bronchopulmonary Dysplasia in Extremely Preterm Neonates
autologous cord blood mononuclear cells - BPD
Phase 3UnknownGuangdong Women and Children Hospital762021-10-012021-10-08
The Budesonide in Babies (BiB) Trial
budesonide (Pulmicort nebulizing suspension)., surfactant (poractant alfa;Curosurf) - Bronchopulmonary Dysplasia (BPD), Respiratory Distress Syndrome
Phase 3Active not recruitingNICHD Neonatal Research Network6422021-04-012026-04-15
Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19
ZYESAMI™ (aviptadil acetate), Placebo, Nebulized administration of ZYESAMI™ or Placebo - SARS-CoV 2, COVID
Phase 2 / Phase 3TerminatedAPR Applied Pharma Research s.a.1442021-02-152023-02-03
Treatment of Classic Mid-trimester PPROM by Means of Continuous Amnioinfusion
Continuous amnioinfusion with Amnion Flush Solution through the intraamniotic catheter - Bronchopulmonary Dysplasia, Necrotizing Enterocolitis
Phase 3UnknownMartin-Luther-Universität Halle-Wittenberg682021-01-012021-01-12

Showing 20 of 92. Sign in to see all of them.

Narrower conditions

Bronchopulmonary Dysplasia (45)  ·  Acute Lung Injury (32)  ·  Respiratory Distress Syndrome (31)  ·  Premature Birth (21)  ·  Respiratory Insufficiency (8)  ·  COVID-19 (7)  ·  Lung Diseases (6)  ·  Meconium Aspiration Syndrome (5)  ·  Sepsis (5)  ·  Respiratory Tract Diseases (4)  ·  Ventilator-Induced Lung Injury (4)  ·  Coronavirus Infections (3)  ·  Dyspnea (3)  ·  Leukomalacia, Periventricular (3)

Broader conditions

Respiratory Tract Diseases (88)  ·  Lung Diseases (86)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (52)  ·  Infant, Newborn, Diseases (48)  ·  Infant, Premature, Diseases (47)  ·  Ventilator-Induced Lung Injury (44)  ·  Respiration Disorders (37)  ·  Female Urogenital Diseases and Pregnancy Complications (27)  ·  Urogenital Diseases (27)  ·  Pregnancy Complications (26)  ·  Obstetric Labor Complications (21)  ·  Obstetric Labor, Premature (21)  ·  Pathological Conditions, Signs and Symptoms (20)  ·  Infections (18)

Interventions

Sodium Chloride (7)  ·  Saline Solution (6)  ·  Budesonide (4)  ·  Endothelium-Dependent Relaxing Factors (4)  ·  Hydrocortisone (3)  ·  Methylprednisolone (3)  ·  Nitric Oxide (3)  ·  Standard of Care (3)  ·  Surface-Active Agents (3)  ·  aviptadil (3)  ·  Azithromycin (2)  ·  Continuous Positive Airway Pressure (2)  ·  Dexamethasone (2)  ·  Oxygen (2)  ·  Palivizumab (2)

Sponsors

NICHD Neonatal Research Network (8)  ·  National Heart, Lung, and Blood Institute (NHLBI) (7)  ·  APR Applied Pharma Research s.a. (3)  ·  Assistance Publique - Hôpitaux de Paris (2)  ·  Guangdong Women and Children Hospital (2)  ·  Mallinckrodt (2)  ·  McMaster University (2)  ·  Roberta Ballard (2)  ·  The University of Texas Health Science Center, Houston (2)  ·  University of Alabama at Birmingham (2)  ·  University of Colorado, Denver (2)  ·  AO GENERIUM (1)  ·  AbbVie (1)  ·  Abbott (1)  ·  Abbott Nutrition (1)

Countries

United States (43)  ·  Canada (12)  ·  France (11)  ·  China (8)  ·  Belgium (6)  ·  Germany (6)  ·  Italy (6)  ·  United Kingdom (6)  ·  Netherlands (5)  ·  Spain (5)  ·  Austria (3)  ·  Israel (3)  ·  Russia (3)  ·  Sweden (3)  ·  Australia (2)

Top investigators

Seetha Shankaran, MD (7)  ·  Avroy A. Fanaroff, MD (5)  ·  Barbara J. Stoll, MD (5)  ·  Edward F. Donovan, MD (5)  ·  Richard A. Ehrenkranz, MD (5)  ·  Sheldon B. Korones, MD (5)  ·  Charles R. Bauer, MD (4)  ·  David K. Stevenson, MD (4)  ·  Lu-Ann Papile, MD (4)  ·  James A. Lemons, MD (3)  ·  Jon E. Tyson, MD MPH (3)  ·  Jonathan C Javitt, MD, MPH (3)  ·  Waldemar A. Carlo, MD (3)  ·  William Oh, MD (3)  ·  Aaron Chiu, MD (2)

Results publications

PMID 27440140, PMID 22307571, PMID 10400143, PMID 10545589, PMID 10802492, PMID 11150359, PMID 11416871, PMID 12219057, PMID 14510322, PMID 14993550, PMID 15767942, PMID 16014597, PMID 16651303, PMID 16870913, PMID 16870914, PMID 16939737, PMID 17307536, PMID 17426195, PMID 18245420, PMID 19117884, PMID 19713451, PMID 19841125, PMID 19841128, PMID 20138299, PMID 20405117, PMID 20472937, PMID 20472939, PMID 20587676, PMID 20591191, PMID 20633284, PMID 21562125, PMID 21976613, PMID 22059409, PMID 22120766, PMID 22371462, PMID 22738947, PMID 22943074, PMID 23268664, PMID 23339639, PMID 23944299, PMID 24289974, PMID 24335442, PMID 24388320, PMID 24725582, PMID 24835849, PMID 24876196, PMID 24996573, PMID 25425651, PMID 25554820, PMID 25647203

NIH funding

U10HD021373 (7), U10HD021385 (7), U10HD027853 (7), U10HD027880 (7), U10HD021364 (6), U10HD021397 (6), U10HD027851 (6), U10HD027856 (6), U10HD027871 (6), U10HD027904 (6), M01RR000750 (5), M01RR008084 (5), U10HD021415 (5), U10HD027881 (5), U10HD034216 (5)